Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Evaluation committee members The highly specialised technologies (HST) committee is a standing advisory committee of NICE. This topic was considered as a cost comparison evaluation by the lead team of ...

Vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) is available on the NHS as a possible treatment for cystic fibrosis. It is for people 6 years and over who have at least 1 F508del mutation in the ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...

1 Purpose of this document NICE's early value assessment guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments ...

Status: Awaiting development Technology type: Medicine Decision: Selected Reason for decision: Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the ...

Suggested remit: To appraise the clinical and cost effectiveness of olezarsen within its marketing authorisation for treating familial chylomicronaemia syndrome. Key events during the development of ...